If your objective is to lose fat and gain muscle there are a few options to choose from one of our favorites is a peptide called CJC/Ipamorelin. CJC/Ipamorelin is a growth hormone releasing peptide. There are less side effects and appetite stimulation than traditional human growth hormone. Unlike other growth hormone releasing options this peptide doesn’t release the same volume of cortisol, acetylcholine, prolactin and aldosterone. It is one of the only selective growth hormone releasing options. With CJC and Ipamorelin being used together the benefits are maximized 5x what they would be used singularly. CJC and Ipamorelin have different ways of working on different receptors (GHRH-R and Ghrelin-R).
Clinical Studies:
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC 1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, and Lawrence A. Frohman. WinPharm Associates (S.L.T., A.N.), Alamo, California 94507; ConjuChem, Inc. (B.L., C.G., J.-P.C.), Montre´al, Que´be´c, Canada; and Section of Endocrinology, Department of Medicine, University of Illinois (L.A.F.), Chicago, Illinois 60612
Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.
Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC 1295, a long-acting GHRH analog.
Design: The study design was two randomized, placebo-controlled, double blind, ascending dose trials with durations of 28 and 49 d.
Setting: The study was performed at two investigational sites.
Participants: Healthy subjects, ages 21–61 yr, were studied.
Conclusions: CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated. There was evidence of a cumulative effect after multiple doses.
These data support the potential utility of CJC 1295 as a therapeutic agent. (J Clin Endocrinol Metab 91:799–805, 2006)
A full copy of all trials are available from Tailor Made Compounding Pharmacy.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Source: Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, US
Purpose: To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers.
Results: The PK parameters showed dose-proportionality, with a short terminal half-life of 2 hours, a clearance of 0.078 L/h/kg and a volume of distribution at steady-state of 0.22 L/kg. The time course of GH stimulation by ipamorelin showed a single episode of GH release with a peak at 0.67 hours and an exponential decline to negligible GH concentration at all doses. The ipamorelin-GH concentration relationship was characterized using an indirect response model and population fitting. The model employed a zero-order GH release rate over a finite duration of time to describe the episodic release of GH. Ipamorelin induces the release of GH at all dose levels with the concentration (SC50) required for half-maximal GH stimulation of 214 nmol/L and a maximal GH production rate of 694 mIU/L/h. The interindividual variability of the PD parameters was larger than that of the PK parameters.
Conclusions: The proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses.
A full copy of all trials are available from Tailor Made Compounding Pharmacy.